The points below describe potential research-observed benefits , not approved medical or therapeutic claims
That is, compared to insulin, 57 and 30 patients would need to be treated with a GLP-1RA for a mean of 2.3 years to prevent one case of all-cause mortality and hospitalized hypoglycemia, respectively, which would cost US$54,851 and US$29,115 per case of all-cause mortality and hospitalized hypoglycemia prevented, respectively, from the payer perspective, and would save US$19,391 and US$10,293, respectively, from the healthcare sector perspective
The earliest it could hit the market would be late 2026, though it's more likely to drop in 2027
This means that it is not possible to overdose on vitamin B12, and as far as we know there is no upper limit on the amount of B12 that can be taken safely by an otherwise healthy person
Published in 2025, the study concluded that tesamorelin can lead to a significant reduction in such risk among people with HIV, a population whose likelihood of a cardiovascular event is twice as high compared to the general population.24 Skin health While you wont find any direct clinical studies on tesamorelin and skin health, there are several publications discussing the relationship between growth hormone, IGF-1, and skin-related health concerns
A Head-to-Head Study The Lilly-sponsored SURMOUNT-5 study compared weight loss with tirzepatide vs semaglutide